^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IGM-2644
i
Other names: IGM-2644, CD38 x CD3 based IgM bispecific antibody, IGM2644, IGM 2644
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
IGM Biosciences
Drug class:
CD3 agonist, CD38 inhibitor
Related drugs:
5ms
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=4, Terminated, IGM Biosciences, Inc. | N=100 --> 4 | Trial completion date: Aug 2026 --> Feb 2024 | Recruiting --> Terminated | Trial primary completion date: Mar 2026 --> Feb 2024; Company Decision
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
IGM-2644
over1year
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=100, Recruiting, IGM Biosciences, Inc.
New P1 trial
|
IGM-2644
over1year
HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING (EHA 2023)
Our preclinical data indicate that IGM-2644 maintains activity in the presence ofdaratumumab. A Phase 1 clinical trial in r/r MM is being planned to evaluate the safety and pharmacokinetics of IGM-2644. The clinical study will evaluate these preclinical findings, including the treatment of patients with circulating serum levels of daratumumab.
IO biomarker
|
CD38 expression
|
Darzalex (daratumumab) • IGM-2644
Share via
